AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

CORRECTING and REPLACING Bioasis Announces Filing of Its Quarterly Financial Statements and MD&A for the Period Ending August 31, 2019

October 25, 2019

GUILFORD, Conn.--(BUSINESS WIRE)--Oct 25, 2019--

First paragraph, first sentence of release should read: Bioasis Technologies Inc.  (TSX.V:BTI; OTCQB:BIOAF) (the “Company” or “Bioasis”), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB 3 TM  platform technology for the delivery of therapeutics across the blood-brain barrier (“BBB”) and the treatment of central nervous system (“CNS”) disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases, today announced it has filed its unaudited financial statements and management’s discussion and analysis for the period ended August 31, 2019 (instead of...today announced it has filed its audited annual financial statements and management’s discussion and analysis for the period ended August 31, 2019).

The corrected release reads:

BIOASIS ANNOUNCES FILING OF ITS QUARTERLY FINANCIAL STATEMENTS AND MD&A FOR THE PERIOD ENDING AUGUST 31, 2019

Bioasis Technologies Inc.  (TSX.V:BTI; OTCQB:BIOAF) (the “Company” or “Bioasis”), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB 3 TM  platform technology for the delivery of therapeutics across the blood-brain barrier (“BBB”) and the treatment of central nervous system (“CNS”) disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases, today announced it has filed its unaudited financial statements and management’s discussion and analysis for the period ended August 31, 2019. All are available under the Company’s profile on SEDAR at www.sedar.com and on the Company’s website at www.bioasis.us/investors/.

ABOUT BIOASIS

Bioasis Technologies Inc. is a biopharmaceutical company developing the xB 3TM platform, a proprietary technology for the delivery of therapeutics across the BBB and the treatment of CNS disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases. The delivery of therapeutics across the BBB represents the final frontier in treating neurological disorders. The in-house development programs at Bioasis are designed to develop symptomatic and disease-modifying treatments for brain-related diseases and disorders. The company maintains headquarters in Guilford, Conn., United States. Bioasis trades on the TSX Venture Exchange under the symbol “BTI” and on the OTCQB under the symbol “BIOAF.” For more information about the company, please visit www.bioasis.us.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

View source version on businesswire.com:https://www.businesswire.com/news/home/20191025005475/en/

CONTACT: On behalf of the Board of Directors of Bioasis Technologies Inc.

Deborah Rathjen, Ph.D., Director and President & Chief Executive Officer

deborah@bioasis.us

+1 203 533 7082

KEYWORD: CONNECTICUT UNITED STATES NORTH AMERICA

INDUSTRY KEYWORD: PROFESSIONAL SERVICES HEALTH FINANCE GENERAL HEALTH PHARMACEUTICAL BIOTECHNOLOGY

SOURCE: Bioasis Technologies Inc.

Copyright Business Wire 2019.

PUB: 10/25/2019 05:44 PM/DISC: 10/25/2019 05:44 PM

http://www.businesswire.com/news/home/20191025005475/en